How My Autoimmune Conditions Taught Me to Take Infection Risks Seriously

-



antibiotics for infection :: Article Creator

New Phage Therapy Treatment Can Treat Antibiotic-resistant Infections In All Animals

Antibiotics are still the first line of treatment for infections in animals and humans, but as these drugs are overused, many bacteria become resistant to them. 

Now, for the first time, an Israeli Persian cat has undergone personalized bacteriophage therapy that uses its genetic profile to guide decisions made for disease prevention, diagnosis, and treatment.

Bacteriophages ("phages" for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections, especially those that cannot be treated with antibiotics. 

The therapy is personalized because the specific phages used are tailored to the individual patient's infection, as determined through bacterial culture and genetic analysis.

In 2010, the first report of a veterinary clinical trial of a phage-based infection treatment was published. Ten dogs with chronic ear infections were treated with a cocktail of six phages active against the bacterium P. Aeruginosa. 

Treatment process. (credit: Milat and Larry Berkley)

The technique has also been used in cows, chickens, and other farm animals. The US Food and Drug Administration (FDA) has approved the use of general phage therapy in the food industry, largely in the dairy and meat industry, to combat bacterial growth. 

But this was only a general—not personalized—treatment that did not involve tailoring the phage to the animals' genetic profile, so it was not very successful. 

A new study led by Prof. Ronen Hazan and his team from the Faculty of Dental Medicine at the Hebrew University of Jerusalem (HUJI), in collaboration with the team of Vet Holim – the Veterinary Medical Center in Kiryat Anavim just outside Jerusalem – has achieved a significant advancement in the treatment of antibiotic-resistant infections in animals. 

Interestingly, unlike common situations, this case was performed on an animal based on doctors' insights from treating humans first. 

Therapy has been published in veterinary medicine journal 

The team just published their innovative therapy in the journal Veterinary Quarterly under the title "Successful phage-antibiotic therapy of P. Aeruginosa implant-associated infection in a Siamese cat." The team included Ron Braunstein, Goran Hubanic, Ortal Yerushalmy, Sivan Oren-Alkalay, Amit Rimon, and Shunit Coppenhagen-Glazer. 

Their treatment involved a five-year-old Siamese cat named Squeaks who suffered from an infection with Pseudomonas aeruginosa bacteria (that infects humans as well as canines) after undergoing arthrodesis surgery on a damaged joint cartilage to fuse two leg bones together. After the surgery, the area of bone where the joint was positioned is no longer capable of motion, and the pet is relieved of severe pain. 

Squeaks, initially treated at the Kiryat Anavim veterinary hospital for injuries sustained from a high-rise fall, developed a severe infection in the right hind leg following multiple operations. This infection persisted despite various antibiotic treatments over four months. 

Facing a potential implant-replacement surgery, the team turned to the new treatment which involved a meticulously designed combination of a specific anti-P. Aeruginosa phage, a virus that kills bacteria, applied topically to the surgical wound, with ceftazidime (an injected, broad-spectrum third-generation cephalosporin beta-lactam antibiotic) administered with a needle into the muscle. After receiving instructions, the cat's owners gave Squeaks most of the treatment doses of phages and antibiotics at their home.

The integration of phage therapy with antibiotics was aimed at targeting the pathogen effectively and directly at the site of infection, leveraging the phage's ability to be applied topically, which simplifies administration and maximizes its concentration at the infection site. This approach allowed the surgical wound, which had remained open for five months, to fully heal after 14 weeks of treatment.

The successful outcome of this case underscores the critical need for novel therapeutics like personalized phage therapy to cope with the growing concern of antibiotic-resistant infections that affect up to 8.5% of surgical sites following orthopedic surgeries in pets. These infections pose significant health risks to the animals and increase the suffering, deaths, and costs involved in these procedures.

Recent studies suggest that phage therapy, already showing high success rates in human medicine for treating orthopedic infections and chronically infected wounds, can offer a promising solution for similar issues in veterinary practice. Moreover, the successful treatment of this cat by its owners at home highlights the practicality and efficacy of personalized phage therapy, which could be extended to treat other pets facing similar antimicrobial resistance challenges, the authors wrote. 

The positive reception from veterinarians and pet owners regarding phage therapy indicates growing awareness and acceptance of this treatment option. "As the new treatment continues to be explored in veterinary settings, it not only improves the health and well-being of pets but also offers valuable data that contribute to the broader application of phage therapy in both animals and humans," they continued. This bridging of data can enhance treatment protocols and outcomes across various bacterial infections, potentially changing the landscape of infection treatment in both veterinary and human medicine."

Braunstein told The Jerusalem Post that the vet hospital treated Squeaky for free because it was the first case and that the team is ready to accept any pet—even a snake, dog, gerbil, rabbit, or others—for treatment if it suffers from a persistent bacterial infection that is not healing after being treated with antibiotics. 


Suppressive Antibiotics For Joint Infections: Benefit Debate Unveiled

16th May 2024

1 Mins

Microbiology & Infectious Diseases

BENEFITS of suppressive antibiotic therapy (SAT) may be limited, according to new research. SAT is a routine strategy for managing periprosthetic joint infections (PJI), but determining the optimal duration of treatment presents a challenge for clinicians, particularly when the implant is retained. The debate centres on whether indefinite antibiotic therapy or a fixed treatment duration is more appropriate.

In this study, the research team conducted a multicentre retrospective study to investigate the efficacy of SAT in managing PJIs. They assessed patients with acute PJI of the hip or knee who underwent debridement, antibiotics, and implant retention (DAIR) across centres in Europe and the USA. The study included 510 patients: 167 who received SAT and 343 who did not.

No significant association was found between SAT and treatment failure at 12 weeks (hazard ratio: 1.37; 95% confidence interval: 0.79–2.39). Subgroup analyses for specific joint, country cohort, and infection type showed no overall benefit for SAT; however, a secondary analysis focused on country cohorts revealed a potential trend towards benefit for patients in the USA (hazard ratio: 0.36; 95% confidence interval: 0.11–1.15); where it was determined that more than half of treatment failures occurred.

"Not all patients who undergo DAIR for PJI should receive indefinite suppressive antibiotic therapy after completing the initial 12-week treatment course," said lead researcher Don Bambino Geno Tai, University of Minnesota Medical School, Minneapolis, USA. "The decision to prescribe long-term suppressive antibiotics should be made carefully, taking into account each individual patient's specific characteristics and risk factors."

While there was no clear advantage overall, SAT may be more beneficial for specific patient groups, particularly in regions with higher rates of treatment failure. Clinicians should carefully consider individual patient characteristics and risk factors before prescribing long-term suppressive antibiotics following the initial 12-week treatment course.

Reference

Tai DBG et al. Role of routine suppressive antibiotic therapy after DAIR for acute periprosthetic joint infections. Open Forum Infect Dis. 2024;DOI:10.1093/ofid/ofae216.


Antibiotic Resistance Markets Therapeutics, By Pathogen And Therapy Type To 2027: Search For Alternatives To Antibiotics Creates New Global Goldrush

Company Logo

Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2023 to 2027" report has been added to ResearchAndMarkets.Com's offering.

Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. The report has identified the 6 Key Large Opportunities in this space and developed market forecasts.

The report has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. The report summarizes what technologies they are using.

Make investment decisions and valuations with confidence using the latest data. The report includes five-year market forecasts.

Key Topics Covered:

Overview of a Dynamic Market

  • Market Players - Roles & Impacts

  • Understanding Antimicrobial Resistance

  • The Changing Road to New Antibiotics & Technologies

  • The Key Role of Diagnostics in AMR

    • The Key Large Market Opportunities in AMR

  • Streptococcus Pneumoniae (DRSP)

  • Campylobacter (DRC)

  • Clostridium Difficile (CD)

  • Staphylococcus aureus (MRSA)

  • Neisseria gonorrhoeae (DRNG)

  • Salmonella (DRNTS)

    • Therapeutic Technology Development Opportunities

    Antibiotic Resistance Recent Developments

  • Bacteriophage May Combat AMR

  • Shionogi to Acquire Qpex Biopharma

  • Adaptive Phage Therapeutics to Fight Antibiotic Resistance

  • Smartbax to create next-generation antibiotics

  • Startup Solu raises €1M to combat AMR

  • Akthelia Pharma and University of Iceland to Combat AMR

  • WHO warns of too few new Antibiotics

  • Bactobio Raises £6 Million To Discover Novel Antimicrobials

  • AMR triggers race to develop phages

  • AMR Pandemic Overlooked

  • New resistance-busting antibiotic combination

  • CDC Awards $22M to Combat Antimicrobial Resistance

  • Antibiotic resistance outwitted by supercomputers

  • STIs Reach Record Highs

  • New research using nanoparticles to bolster waning antibiotics

  • OpGen Receives FDA Clearance for AMR Panel

  • CDC Updates STI Diagnosis, Treatment Guidelines

  • Positive associations between AM use in animals and AMR in humans

  • PEW Antibiotic Pipeline Findings

    • Story continues

    Key Biotechnology Companies and Their Technology

  • Melinta Therapeutics

  • Arsanis

  • Phage Technologies S.A

  • Westway Health

  • Tetraphase Pharmaceuticals

  • BioVersys GmbH

  • Nabriva Therapeutics

  • Macrolide Pharmaceuticals

  • Nemesis Bioscience

  • C3J Therapeutics, Inc.

  • EpiBiome

  • discuva

  • SmartPhage.

  • AmpliPhi Biosciences

  • Pherecydes Pharma

  • Micreos

  • Procarta Biosystems

  • Lumavita

  • Madam Therapeutics

  • Priaxon

  • Biolytx Pharmaceuticals

  • AntibioTx

  • Xellia Pharmaceutials

  • Paratek Pharmaceuticals

  • Synereca Pharmaceuticals

  • Allecra Therapeutics

  • Fixed Phage

  • Enanta Pharmaceuticals, Inc.

  • Demuris

  • Prommune

  • Biosergen

  • Innovation Pharmaceuticals

  • Aviragen Therapeutics

  • Achillion Pharmaceuticals

  • ImmunNovative Developments, S.L.

  • Achaogen, Inc.

  • SelectX Pharmaceuticals, Inc.

  • TaiGen Biotechnology Co., Ltd.

  • Theravance Biopharma

  • Abbvie

  • KYORIN Pharmaceutical Co.,Ltd.

  • Iterum Therapeutics Limited

  • Forge Therapeutics

  • Alopexx Vaccine LLC

  • Integrated Biotherapeutics

  • Hennepin Life Sciences

  • Fedora Pharmaceuticals Inc.

  • Contrafect Corporation

  • Basilea Pharmaceutica Ltd.

  • AiCuris

  • RedHill Biopharma

  • Redx Pharma Plc/Redx Anti Infectives Ltd.

  • ABAC Therapeutics

  • Alaxia SAS

  • Antabio S.A.S

  • Auspherix Ltd

  • BioFilm Pharma

  • Centauri Therapeutics Ltd

  • Combioxin SA

  • Da Volterra

  • Debiopharm International SA

  • Deinobiotics/Deinove

  • Destiny Pharma plc

  • Eligo Bioscience

  • Helperby Therapeutics Ltd

  • Karveel Pharmaceuticals

  • MaaT Pharma

  • Motif BioSciences, Inc/Motif Bio PLC

  • Mutabilis SAS

  • Neem Biotech Ltd

  • Northern Antibiotics Oy (Ltd)

  • Nosopharm

  • NovaBiotics Ltd

  • Phico Therapeutics Ltd

  • Polyphor Ltd

  • QureTech Bio AB

  • SetLance srl

  • Ultupharma AB

  • Vaxdyn

  • Vibiosphen

  • Bioaster

  • Vivexia

  • KBP Biosciences

  • Absynth Biologics

  • Spero Therapeutics

  • Merck

  • Symphogen

  • Warp Drive Bio.

  • Johnson & Johnson (Janssen)

  • Pfizer

  • Allergan

  • GlaxoSmithKline

  • Novartis

  • Gilead Sciences

  • AstraZeneca

  • Sanofi

  • Shionogi Inc.

  • Cipla

  • DSM Sinochem Pharmaceuticals

  • Wockhardt Ltd.

  • VenatoRx Pharmaceuticals

  • MicuRx

  • Entasis Therapeutics

  • Merlion Pharmaceuticals

  • Aridis Pharmaceuticals Inc.

    • Market Sizes by Pathogen

  • DRSP Market

  • DRC Market

  • CD Market

  • MRSA Market

  • DRNG Market

  • DRNTS Market

  • Other Pathogen Market

    • The Future of AMR

    For more information about this report visit https://www.Researchandmarkets.Com/r/km7mm3

    About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

    CONTACT: CONTACT: ResearchAndMarkets.Com Laura Wood,Senior Press Manager press@researchandmarkets.Com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

    View comments





    Comments

    Post a Comment

    Popular posts from this blog

    Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

    -
    Image
    A rash behind the ear may occur due to a variety of different medical conditions. Certain viral infections and autoimmune diseases may cause a rash behind the ear in both children and adults. While some causes, such as contact dermatitis, are not concerning, other causes, including rubella, may be more serious. In this article, we look at some of the causes of a rash behind the ear, as well as the other symptoms that they may produce and how to treat them. Contact dermatitis is an allergic reaction to a particular substance. If an allergy-inducing substance comes into contact with the skin behind the ear, a rash can form. Allergens that may cause contact dermatitis behind the ears include: shampoos soaps other hair care products For example, hair dye products contain an ingredient called paraphenylenediamine (PPD), which is a common contact allergen. Symptoms Contact dermatitis causes itchiness, dryness, and flaking of the skin that came into contact with the allergen. Diagnosis A doc
    Read more

    Manual on meat inspection for developing countries

    -
    Image
    bcg vaccine use :: Article Creator Merck May Have A Competition For Ever-scarce BCG Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Today, we learn more about studying tumors at the International Space Station, study the buzzy Amgen weight loss drug MariTide, and find a lawsuit in which a former Spark Therapeutics executive is accusing ex-colleagues of sexism. The need-to-know this morning Pfizer appointed Andrew Baum as its new chief strategy and innovation officer. Baum joins Pfizer from the investment bank Citi, where he served as head of global healthcare research. He is joining Pfizer's executive committee and will report to Chairman and CEO Albert Bourla. In a mid-stage study, EyePoint Pharmaceuticals said its eye drug Duravyu failed to improve disease control compared to a sham injection in patients with non-proliferative diabetic retinopathy.
    Read more

    Freddie Mercury's haunting last picture before tragic death from Aids - Irish Mirror

    -
    Freddie Mercury's final days in 1991 remain enshrined in mystery, nearly 30 years on. The Queen frontman succumbed to his battle with Aids on November 24, having released a public statement just 24 hours previously that confirmed he was HIV+. Rumours had been swirling about his health status for a number of years, with speculation that he had been tested for HIV and Aids as far back as 1986, after his health declined so rapidly that Queen had to halt their 1987 Magic Tour before it was due to finish. Freddie, real name Farrokh Bulsara, had been something of a recluse in his last two years, preferring to stay at his lavish Garden Lodge home in west London's Kensington than rub shoulders with other celebrities at showbiz parties. Tragically, Freddie's health continued to deteriorate in private, as feverish speculation mounted that he was gravely sick. The last known photos of him show how much weight he had lost during his rare public appearances towards the end. On Sep
    Read more